HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.

Abstract
Glucagon-like peptide-1 (GLP-1)-based therapies have demonstrated efficacy and safety in treating type 2 diabetes, which shares a similar pathophysiological mechanism with non-alcoholic fatty liver disease (NAFLD). Recent studies showed that glucose-induced GLP-1 secretion was decreased in patients with NAFLD and that the level of dipeptidyl peptidase-4, which inactivates intact GLP-1, was upregulated. Moreover, the expression of the GLP-1 receptor was downregulated in livers from patients with NAFLD, indicating an association of defective GLP-1 signalling with NAFLD. Notably, GLP-1-based therapies are reported to be effective in improving hepatic endpoints in patients with NAFLD, such as reducing hepatic fat content, hepatic steatosis and plasma transaminase levels, and preventing fibrosis. GLP-1-based therapies are beneficial for body weight control and glycaemic normalisation, which are important for the management of NAFLD. Moreover, clinical and preclinical studies showed that GLP-1-based agents might directly exert their actions on the liver through activation of functional GLP-1 receptors in hepatocytes. The possible mechanisms involve regulating gene expression that is associated with insulin resistance and lipid metabolism, and suppressing oxidative stress in the liver cells, thus preventing the development and progression of NAFLD. Based on these promising data, large-scale randomised controlled trials are warranted to assess the efficacy and safety of GLP-1-based therapies in treating NAFLD.
AuthorsYe Liu, Rui Wei, Tian-Pei Hong
JournalWorld journal of gastroenterology (World J Gastroenterol) Vol. 20 Issue 27 Pg. 9090-7 (Jul 21 2014) ISSN: 2219-2840 [Electronic] United States
PMID25083081 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antioxidants
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Incretins
  • Receptors, Glucagon
  • Glucagon-Like Peptide 1
Topics
  • Animals
  • Antioxidants (therapeutic use)
  • Glucagon-Like Peptide 1 (metabolism)
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Hypolipidemic Agents (therapeutic use)
  • Incretins (therapeutic use)
  • Insulin Resistance
  • Lipid Metabolism (drug effects)
  • Liver (drug effects, metabolism)
  • Non-alcoholic Fatty Liver Disease (drug therapy, metabolism, physiopathology)
  • Oxidative Stress (drug effects)
  • Receptors, Glucagon (agonists, metabolism)
  • Signal Transduction (drug effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: